Who
Alsup Laurie Smaldone
Director
Company insider
Files Form 4 as: Director, Theravance Biopharma; Director, Arvinas; Director, BlackBerry; Director, Kinnate Biopharma; Director, Pardes Biosciences; Director, Kalobios Pharmaceuticals.
In numbers
- Trades disclosed
- 93
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 6
- Companies where not an officer
- 6
- First trade
- 22 Oct 2013
- Last trade
- 23 Sep 2026
- Last filed
- 24 Sep 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 23 Sep 2026filed 24 Sep 2026 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Code D | —74,980 | filing |
| 23 Sep 2026filed 24 Sep 2026 | Theravance Biopharmaoption or derivative · Pharmaceuticals | SEC FORM 4 Code D | —23,576 | filing |
| 23 Sep 2026filed 24 Sep 2026 | Theravance Biopharmaoption or derivative · Pharmaceuticals | SEC FORM 4 Code D | —24,258 | filing |
| 23 Sep 2026filed 24 Sep 2026 | Theravance Biopharmaoption or derivative · Pharmaceuticals | SEC FORM 4 Code D | —13,398 | filing |
| 23 Sep 2026filed 24 Sep 2026 | Theravance BiopharmaPharmaceuticals | SEC FORM 4 Code D | —6,009 | filing |
| 23 Sep 2026filed 24 Sep 2026 | Theravance Biopharmaoption or derivative · Pharmaceuticals | SEC FORM 4 Code D | —13,500 | filing |
| 23 Sep 2026filed 24 Sep 2026 | Theravance Biopharmaoption or derivative · Pharmaceuticals | SEC FORM 4 Code D | —13,500 | filing |
| 23 Sep 2026filed 24 Sep 2026 | Theravance Biopharmaoption or derivative · Pharmaceuticals | SEC FORM 4 Code D | —6,000 | filing |
| 23 Sep 2026filed 24 Sep 2026 | Theravance Biopharmaoption or derivative · Pharmaceuticals | SEC FORM 4 Code D | —6,000 | filing |
| 23 Sep 2026filed 24 Sep 2026 | Theravance Biopharmaoption or derivative · Pharmaceuticals | SEC FORM 4 Code D | —6,000 | filing |
| 23 Sep 2026filed 24 Sep 2026 | Theravance Biopharmaoption or derivative · Pharmaceuticals | SEC FORM 4 Code D | —6,000 | filing |
| 23 Sep 2026filed 24 Sep 2026 | Theravance Biopharmaoption or derivative · Pharmaceuticals | SEC FORM 4 Code D | —28,000 | filing |
| 23 Sep 2026filed 24 Sep 2026 | Theravance Biopharmaoption or derivative · Pharmaceuticals | SEC FORM 4 Code D | —22,044 | filing |
| 23 Sep 2026filed 24 Sep 2026 | Theravance Biopharmaoption or derivative · Pharmaceuticals | SEC FORM 4 Code D | —23,576 | filing |
| 23 Sep 2026filed 24 Sep 2026 | Theravance Biopharmaoption or derivative · Pharmaceuticals | SEC FORM 4 Code D | —24,258 | filing |
| 23 Sep 2026filed 24 Sep 2026 | Theravance Biopharmaoption or derivative · Pharmaceuticals | SEC FORM 4 Code D | —13,398 | filing |
| 23 Sep 2026filed 24 Sep 2026 | Theravance Biopharmaoption or derivative · Pharmaceuticals | SEC FORM 4 Code D | —6,000 | filing |
| 23 Sep 2026filed 24 Sep 2026 | Theravance Biopharmaoption or derivative · Pharmaceuticals | SEC FORM 4 Code D | —6,000 | filing |
| 23 Sep 2026filed 24 Sep 2026 | Theravance Biopharmaoption or derivative · Pharmaceuticals | SEC FORM 4 Code D | —6,000 | filing |
| 23 Sep 2026filed 24 Sep 2026 | Theravance Biopharmaoption or derivative · Pharmaceuticals | SEC FORM 4 Code D | —6,000 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.